viewAequus Pharmaceuticals Inc.

Aequus to broaden patient reimbursement in Canada for glaucoma-treatment product Vistitan

If successful, the additional coverage would advance sales in the second and third largest markets in Canada (Quebec and British Columbia) and increase the total revenue Aequus receives from its partner

Aequus Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc to broaden reimbursement for glaucoma-treatment product Vistitan in Quebec and British Columbia
The Vancouver-based company has been consistently growing market share of Vistitan in Ontario and Alberta

Aequus Pharmaceuticals Inc (CVE:AQS) (OCTMKTS:AQSZF) announced Friday that it has advanced the filings for provincial reimbursement in Quebec and British Columbia for its flagship glaucoma-treatment product Vistitan.

If successful, the company noted that the additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that Aequus receives from its partner.

Meanwhile, investors cheered the news, sending Aequss shares up 10% to US$0.07 in morning trading on the OTC markets in New York.

READ: Aequus and Medicom Healthcare ink pact to advance ophthalmology products in US

Aequus has been consistently growing market share of Vistitan in Ontario and Alberta and is continuing its expansion of access for Canadian patients in both British Columbia and Quebec. 

“The bimatoprost market in Canada exceeds $55 million, nearly 36% of that is in these two provinces,” CEO Doug Janzen said in a statement. 

“Whilst our sales team has done a great job in Ontario and Alberta growing our volume share by over 30% in the last 12 months, we want to replicate that in both Quebec and BC following an anticipated positive reimbursement outcome.”

Ian Ball, chief commercial officer at Aequus, said the additional coverage benefits the company in two ways.

“There is a compelling case for Vistitan reimbursement in Canada and we look forward to a decision shortly from BC and later in the year from INNESS in Quebec,” he said. 

“In addition to expanding the markets for Vistitan, the company will also earn an increase in the revenue share from our partner Sandoz and expects to further bolster our ophthalmology offering with the launch of the Evolve products in the coming months.”

The company said it will provide a further update on the anticipated launch timelines for Evolve by the end of January, as a final notification from the auditor is expected by its partner.

Aequus, based in Vancouver, is a specialty pharma company focused on commercializing drugs meant for the highly specialized areas of neurology, organ transplant and ophthalmology.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.11 CAD

Market: TSX-V
Market Cap: $12.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...


Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

on 19/10/20

2 min read